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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To investigate the effects of educational interventions on the behaviour and clinical practice of health professionals, and subsequent
patient outcomes related to prevention of foot ulceration in people with diabetes.
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B A C K G R O U N D
The world is currently facing an epidemic of obesity and type 2
diabetes mellitus (Matthews 2010). The World Health Organiza-
tion (WHO) estimates that the global prevalence of diabetes now
stands at 346 million persons (WHO 2011), but new data from
the International Diabetes Federation (IDF) suggest that the fig-
ure may be as high as 366 million (IDF 2011). Prevalence rates for
diabetes in some countries have already met or exceeded levels pre-
dicted for the year 2030 (Wild 2004; Yang 2010). The magnitude
of the potentially devastating effect of diabetes globally has led to
the suggestion that type 2 diabetes could be the “Black Death” of
the 21st century (Matthews 2010).
Foot complications are one of themost common of themany com-
plications associated with diabetes (IDF 2005). Foot ulcers affect
15% to 25%of individuals with diabetes, and are a leading cause of
hospitalisation for diabetes-related complications (Boulton 2005a;
Singh 2005). They often result in reduced quality of life and pre-
cede up to 85% of lower limb amputations (Singh 2005). Di-
abetes is associated with 25% to 90% of all lower limb ampu-
tations (Global Lower Extremity Study Group 2000), and peo-
ple who undergo diabetes-related amputations usually have five-
year mortality rates of approximately 50% (Armstrong 2007). A
substantial economic burden is associated with the treatment of
diabetic foot ulcers and any resulting amputations. It is estimated
that up to 20% of the total expenditure on diabetes in Europe
and North America might be attributable to diabetic foot ulcers
(Boulton 2005b). Ray 2005 reported international direct costs in
2003 ranged from EUR 204 to EUR 1142 for a standard unin-
fected ulcer, and from EUR 17,130 to EUR 31,998 for a foot
ulcer requiring lower limb amputation. Significant indirect costs
are also associated with diabetic foot complications, due to de-
creased productivity, rehabilitation, home care and preventative
care (Boulton 2005b).
Description of the condition
According to the International Working Group on the Diabetic
Foot (IWGD 2007), diabetic foot ulcers are defined as full thick-
ness wounds that occur below the ankle in a diabetic patient, irre-
spective of duration. Skin necrosis (death) and gangrene are also
included as ulcers in the current classification system. Risk factors
for the development of diabetic foot ulcers include: peripheral neu-
ropathy (nerve damage), foot deformity and minor foot trauma
(Schaper 2003). Ulcers are frequently complicated by impaired
tissue perfusion (poor permeation of oxygen) caused by peripheral
arterial disease, and often become infected (Gershater 2009). Ad-
ditional factors contributing to the development of diabetic foot
ulcers include poor wound healing, white blood cell (leucocyte)
dysfunction and skin disruption due to fungal toe-web infections
(Singh 2005).
Description of the intervention
International guidelines that aim to reduce the incidence of dia-
betic foot ulcers and prevent the development of complications
have been developed and disseminated (Apelqvist 2007; McInnes
2011). Published studies have consistently reported that a range
of proactive foot ulcer prevention and management strategies can
significantly reduce the incidence of poor diabetes-related foot
outcomes, including amputation rates, hospitalisation, bed days
(length of stay), direct healthcare costs, and indirect costs such
as missed days of work (Canavan 2008; Patout 2000; Trautner
2007; van Houtum 2004). These typically involve a multi-layered
approach that includes: optimising diabetic control; screening of
people with diabetes to identify those at risk of developing foot ul-
cers; patient education to promote appropriate self care; provider
education to improve patient care; and multidisciplinary team
management of individuals at risk of, or with existing, foot ulcera-
tion. This approach is generally facilitated by evidence-based clin-
ical pathways and clinical training (Canavan 2008; Patout 2000;
Trautner 2007; van Houtum 2004).
Education has been recommended as a major tool for the preven-
tion of foot complications in people with diabetes (Hunt 2002;
Mayfield 2004; Singh 2005). The approach used has been based
largely on patient education, however, education of healthcare
providers through knowledge transfer programmes and behaviour
change programmes has also been recommended (Dorresteijn
2010). A number of studies (including some clinical trials) have
reported beneficial effects of provider-based foot-care education
on various outcomes in people with diabetes (Jones 2004; Piette
2000; Rith-Najaran 1998). Knowledge transfer programmes in-
volve interventions to provide health professionals with education
with the aim of improving knowledge, andmay ormay not include
an element of behaviour change, such as training on established
protocol, or improving care models. These programmes offer fur-
ther information through the use of workshops, online modules
etc. to health professionals as a means of providing continuing
education in a specific field. Other strategies for provider educa-
tion include training workshops, development of care guidelines
on diabetic foot management and computer-based reminders to
physicians (Jones 2004; Khoury 1998; Rith-Najaran 1998).
How the intervention might work
Health care providers interact with people at high risk for diabetic
foot complications on a frequent basis. A variety of organisations
recommend regular screening of people with diabetes as a strat-
egy to prevent foot complications (Bolton 2008; Mayfield 2004;
Singh 2005). In addition, appropriate treatment of foot lesions or
infections may prevent progression to ulcers or amputation. A lack
of awareness on the part of healthcare professionals with regard to
appropriate screening and treatment practices will lead to unnec-
essary morbidity and high health care costs (Dorresteijn 2010).
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Education of health care providers to ensure appropriate screening
and treatment practices, therefore, should help to prevent initial
foot lesions as well as progression to ulceration.
Why it is important to do this review
There is little evidence to support the effectiveness of specific edu-
cation programs for health professionals in preventing foot ulcers
in people with diabetes (Pedrosa 2004).
Although educational interventions are widely implemented, re-
cent Cochrane reviews have not found strong evidence to sup-
port the effects of patient education or complex interventions in
reducing the occurrence of foot ulcers in people with diabetes
(Dorresteijn 2010). Foot care knowledge and patient behaviour
seem to be positively influenced by education in the short-term,
but the goal of educational interventions is the prevention of
foot ulceration and amputations, and evidence for this is weak
(Dorresteijn 2010).
Current systematic reviews on diabetic foot ulceration focus pri-
marily on wound care and treatment, and patient education
or complex interventions including home monitoring, however,
there are no systematic reviews that evaluate the effects of inter-
ventions focused on the education of healthcare professionals. It is,
therefore, timely to examine the effects of interventions aimed at
educating healthcare professionals for preventing foot ulceration
in people with diabetes.
O B J E C T I V E S
To investigate the effects of educational interventions on the be-
haviour and clinical practice of health professionals, and subse-
quent patient outcomes related to prevention of foot ulceration in
people with diabetes.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include individually and cluster randomised controlled
trials (RCTs), controlled clinical trials (CCTs), controlled before
and after studies (CBAs), and interrupted time series (ITS) studies.
Educational interventions are often complex and include multiple
approaches that may not be have been evaluated by RCTs. The
inclusion of the CCT, CBA and ITS designs will enable us to
capture these other studies. We will exclude all other types of
studies.
Types of participants
Healthcare staff including medical and nursing staff, allied health
professionals, foot-care assistants and others that are involved in
frontline management of people with diabetes at risk of foot ul-
ceration in any healthcare setting (e.g. hospital, clinic, or care es-
tablishment). In order to differentiate between types of health-
care professionals we will use existing descriptions from included
studies. This review is centred on continuing professional devel-
opment for health-service staff, and will excluded all students who
are being trained in the healthcare setting.
Types of interventions
We will consider interventions of education programmes, or pro-
grammes that include distribution of educational materials, work-
shops, short courses, and open learning (didactic, interactive or
mixed) delivered to qualified healthcare professionals either indi-
vidually or as groups. We will include trials comparing additional
training with no additional training or standard practice, or those
that compare knowledge transfer (passive forms of intervening
such as distribution of educational materials) with programmes
directed at changing healthcare professional behaviour.
The review will include, but will not be limited to, studies specif-
ically targeting education for behaviour change or clinical out-
comes with regard to the management of diabetic foot problems.
Interventions described in the included studies will be categorised
as either foot-care specific interventions, or composite diabetes
interventions (education or behaviour change for improving dia-
betes control and reducing complications).
We will consider the following comparisons:
1. Educational intervention compared with no intervention or
usual practice.
2. Transfer of knowledge intervention (e.g. pamphlets,
brochures, online newsletters and continuing medical education)
compared with intervention aimed at behaviour change (e.g.
face-to-face training, workshops, webinars etc.).
Types of outcome measures
The outcomes of this review fall into twomajor categories, namely:
(1) new foot complications, or change in foot complications in
people with diabetes, and (2) and change in knowledge and prac-
tice of healthcare professionals. For all outcomes we will accept
standardmeasures of assessment of foot complications or use of val-
idated instruments (e.g. swab cultures, bone scans, probe-to-bone,
red blood cell (erythrocyte) sedimentation rate, labelled mono-
clonal antibody, magnetic resonance imaging (MRI), plain radio-
graphs, labelled bone scintigraphy, and wound-based clinical scor-
ing systems). Outcome assessment will include both foot-specific
outcomes (ulcers, amputations etc.) as well as healthcare provider
behaviour change. All primary outcomes and selected secondary
outcomes will be used to populate the summary of findings table.
To ensure a temporal relationship between intervention and foot
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complication outcomes we will measure the time between base-
line evaluation, intervention and outcome in order to determine
whether the observed outcome was most probably due to the in-
tervention.
Primary outcomes
The primary outcomes are outcomes of clinical importance to
people with diabetes:
1. Incidence of new foot ulcers, or ulcer recurrence.
2. Incidence of amputations classified as major amputations
(above knee or below knee amputation), and minor amputations
(across the foot (trans-metatarsals) or toe removal (digital)).
Where data are available we will assess the impact of the inter-
vention on the time to ulcer development, or amputation, using
hazard ratios.
Secondary outcomes
The secondary outcomes will include:
1. Occurrence of bacterial or fungal foot infections (assessed
by clinical observation by physician, and or laboratory confirmed
swab cultures).
2. Number, and duration, of hospital admissions for diabetic
foot problems.
3. Change in patients’ knowledge and behaviour pre- and
post-intervention.
4. Change in healthcare professionals’ knowledge and
behaviour (pre- and post-test assessments following
intervention).
5. Change in healthcare professionals’ practice (e.g. routine
foot inspection, educating patients on foot-care practices).
6. New onset neuropathic osteoarthropathy (Charcot’s foot),
or its precursors.
7. Development of hard skin (callus) (i.e. presence of lesions,
or detailed description of the number, location or diameter of
lesions).
8. Resolution of callus.
9. Visits to healthcare provider for foot infections.
Search methods for identification of studies
Electronic searches
Wewill search the following electronic databases to identify reports
of relevant randomised clinical trials:
• The Cochrane Wounds Group Specialised Register (most
recent);
• The Cochrane Central Register of Controlled Trials
(CENTRAL) (The Cochrane Library, latest issue);
• Ovid MEDLINE (1946 to present);
• Ovid EMBASE (1974 to present);
• EBSCO CINAHL (1982 to present).
We will use the following provisional search strategy in The
Cochrane Central Register of Controlled Trials (CENTRAL):
#1 MeSH descriptor Education, Professional explode all
trees
#2 MeSH descriptor Education, Continuing explode all
trees
#3 (professional* NEAR/5 (educat* or training)):ti,ab,kw
#4 ((nurs* or doctor* or physiotherap* or therapist*
or surgeon* or practitioner* or podiatr*) NEAR/5 (educat* or
training)):ti,ab,kw
#5 ((education* or training) NEXT program*):ti,ab,kw
#6 (seminar* or workshop* or course* or open learning):
ti,ab,kw
#7 ((written or printed or oral) NEXT information):ti,ab,kw
#8 (leaflet* or booklet* or pamphlet* or poster*):ti,ab,kw
#9 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #
8)
#10 MeSH descriptor Foot Ulcer explode all trees
#11 MeSH descriptor Diabetic Foot explode all trees
#12 (diabet* NEAR/5 ulcer*):ti,ab,kw
#13 (diabet* NEAR/5 (foot or feet)):ti,ab,kw
#14 (diabet* NEAR/5 wound*):ti,ab,kw
#15 (diabet* NEAR/5 amputat*):ti,ab,kw
#16 (#10 OR #11 OR #12 OR #13 OR #14 OR #15)
#17 (#9 AND #16)
We will adapt this strategy to search Ovid MEDLINE, Ovid EM-
BASE and EBSCO CINAHL. We will combine the Ovid MED-
LINE search with the Cochrane Highly Sensitive Search Strategy
for identifying randomised trials in MEDLINE: sensitivity- and
precision-maximising version (2008 revision) (Lefebvre 2011).We
will combine the EMBASE search with the Ovid EMBASE filter
developed by the UK Cochrane Centre (Lefebvre 2011). We will
combine the CINAHL searches with the trial filters developed by
the Scottish IntercollegiateGuidelinesNetwork (SIGN 2011).We
will not restrict studies with respect to language, date of publica-
tion or study setting.
We will search the following clinical trials registries:
• ClinicalTrials,gov (http://www.clinicaltrials.gov/);
• The WHO International Clinical Trials Registry Platform (
http://apps.who.int/trialsearch/Default.aspx); and
• EU Clinical Trials Register (https://
www.clinicaltrialsregister.eu/).
Searching other resources
We will search the bibliographies of all included trials identified
by the above strategies for further relevant studies.
Data collection and analysis
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Selection of studies
Study titles and abstracts of articles retrieved by the electronic and
handsearches will be read independently by two review authors
(TF and SJ). These will be assessed for eligibility, according to
the inclusion criteria above. Full copies of all references deemed
potentially eligible by any of the review authors will be retrieved
for closer examination. All studies that initially appear to meet the
inclusion criteria from this first screening, but on closer inspection
(full text) do not, will be detailed in the Table of Excluded Stud-
ies with reasons for their exclusion. We will include a PRISMA
flowchart of the data management phase of the review (Liberati
2009).The full text review will be done independently by two re-
view authors (TF and SJ). Disagreements will be settled by a third
review author (PL).
Data extraction and management
Data will be extracted by up to four review authors (PL, SJ, TF,
and DF) independently, who will review each other’s work, in or-
der to minimise data abstraction errors. Data abstraction forms
will be developed: they will be based on the data collection forms
from the Cochrane Effective Practice and Organization of Care
(EPOC) review group (EPOC 2000), and will be modified for
the purposes of this review. We will extract data on study design,
description of the intervention, details about participants (includ-
ing number in each group), length of intervention, definition of
diabetic foot ulcer, all primary and secondary outcomes, setting,
and statistical analysis used. Where possible, we will record rele-
vant socio-demographic variables, including geographic location,
gender, age of person, and category of healthcare professional.
Assessment of risk of bias in included studies
Two review authors (DF and CC) will independently assess the
risk of bias for each study using the following criteria:
For RCTs and CCTs, the methodological quality of study will
be assessed and recorded using the Cochrane Collaboration’s tool
for assessing risk of bias (Higgins 2011a). The tool addresses six
specific domains:
1. Selection bias (random sequence generation, allocation
concealment).
2. Performance bias (blinding of participants and personnel).
3. Detection bias (blinding outcome assessment).
4. Attrition bias (incomplete outcome data).
5. Reporting bias(selective outcome reporting).
6. Other bias(es).
To determine the risk of bias of included studies, we will evaluate
the adequacy of information and likelihood of potential bias for
each criterion. The judgement for each criterion will be assessed
as ’low risk’, ’high risk’, or ’unclear risk’ of bias. In a consensus
meeting, we will discuss and resolve disagreements among the
review authors. If consensus cannot be reached, a third review
author (VW) will make the final decision(s). When important
study information ismissing from trial reports, wewill contact trial
authors to request the information using open-ended questions.
For CBAs, we will use the Risk of Bias Tool from the Cochrane
EPOCGroup (EPOC2013). This tool covers allocation sequence,
similarity of baseline outcome measurement, similarity of base-
line characteristics, incomplete outcome data, blinding of alloca-
tion, protection against contamination, selective outcome report-
ing, and other risks of bias.
Our appraisal criteria for ITS studies will be adapted from the
’Risk of bias’ checklist developed by the Cochrane EPOC Group
(EPOC 2013). In assessing risk of bias in the ITS designs, we will
consider protection against secular changes (including interven-
tion independent of other changes, appropriate data analysis, and
reason for number of pre and post points given), effect on data
collection, knowledge of allocated interventions, incomplete out-
come data, selective outcome reporting, and other biases. Mini-
mum methodological inclusion criteria across all designs will be:
1. Objective measurement of performance or provider
behaviour on a health, or patient, outcome in a clinical, rather
than a test, situation.
2. Relevant and interpretable data are presented or can be
obtained.
Measures of treatment effect
The data extracted from the studies will be entered into Review
Manager 5 (RevMan 2011). A summary table describing the study
characteristics will be completed.
Dichotomous data
For dichotomous data, a 2 x 2 contingency table will be compiled
including the number of participants with each outcome event
and risk ratios (RR) with 95% confidence intervals (CI).
Continuous data
Continuous data will be analysed if means and standard deviations
are available, and there is no clear evidence of significant skewness
(i.e. skewness with a value greater than one) in the distribution.
For continuous outcomes measured identically across studies, an
overall mean difference (MD) and 95% CI will be calculated.
Otherwise, we will use an overall standardised mean difference
(SMD) and 95% CI. SMDs will be calculated using Hedges g
as described in the Cochrane Handbook for Systematic Reviews of
Interventions (Section 7.7.3) (Higgins 2011b).
Unit of analysis issues
Multiple outcomes and designs
We have a number of different outcomes and study designs. Con-
ceptually, these outcomes and designs cannot be combined (for
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example, CBA and RCTs ). Therefore, a meta-analysis will be con-
ducted separately for each outcome. Furthermore, for each out-
come, we will meta-analyse the following separately: 1) developing
versus developed countries (defined as developed/high income or
developing/low and middle income according to the World Bank
classificationWorld 2011); 2) different study designs (ITSs, RCTs,
CCTs, and CBAs). We have chosen to analyse developing versus
developed countries as the two settings are very different in terms
of incidence and prevalence of our primary outcomes, standard of
care, and other contextual factors (follow-up visits, availability of
continuing education to healthcare professionals etc.).
Cluster randomised trials
Where trials have used clustered randomisation, we anticipate that
the study investigators would have controlled appropriately for
clustering effects (for example, variance-inflated standard errors,
and hierarchical linear models) before presenting their results. We
expect, however, that some cluster RCTs may not account for clus-
ter effect in analysis, leading to unit of analysis errors in which P
values can be artificially extreme and confidence intervals overly
narrow. If sufficient data are presented, we will re analyse studies
with potential unit of analysis errors using the Cochrane Hand-
book methods to calculate the variance-inflation factor. We will
search for appropriate intra-class correlation coefficients (ICCs)
from the included studies or authors, or from other published
studies when ICCs are not available from the included studies. If
a comparison is re analysed, we will annotate it as ’re analysed’.
Following this, effect sizes and standard errors will be meta-anal-
ysed in RevMan using the generic inverse method described in the
Cochrane Handbook for Systematic Reviews of Interventions (Section
16.3) (Higgins 2011a).Theywill be combinedwith estimates from
individual level trials.
We will use sensitivity analyses to assess the potential biasing ef-
fects of using the intra-class correlation coefficients that have been
derived in different ways (for example, based on individual patient
data, estimated from other studies).
We will use time series regression to re analyse each comparison
when accounting for unit of analysis errors in ITS designs.
Pre- and post-tests
Whenbaseline data are not available, resultswill be expressed as the
relative or absolute difference between intervention and control
group at follow up (difference between post-intervention values
in the education intervention and control groups expressed as a
percentage of post-intervention values in the control group).
Dealing with missing data
Authors will be contacted to supply missing or unreported data,
such as incidence or rate of infection, standard deviations, details
of attrition or details of education interventions received by the
intervention groups. If outcome data are only reported for partici-
pants completing the trial or who followed protocol, then authors
will be contacted for additional information to enable an analysis
to be conducted according to intention-to-treat principles. Miss-
ing data and attrition will be described for each included study in
the Risk of Bias table. If missing data are unobtainable, the extent
to which the results or conclusions of the review might be affected
by this will be assessed and discussed.
Assessment of heterogeneity
Heterogeneity between trial results will be tested using a standard
Chi2 test, to assess whether observed differences in results are com-
patible with chance alone. The I² test will be used to examine the
percentage of total variation across studies due to heterogeneity
rather than due to chance. Values over 75% indicate a high level of
heterogeneity (Higgins 2003). If substantial heterogeneity is de-
tected, studies will be combined by narrative summary only, and
heterogeneity explored by conducting predefined subgroup anal-
yses.
If heterogeneity exists, we will examine potential sources using the
following steps:
1. Subgroup analysis.
2. Meta-regression.
Assessment of reporting biases
If sufficient studies are found (at least 10 studies), funnel plots will
be drawn to investigate any relationship between effect size and
trial size. Asymmetry in the plots could be due to publication bias,
but could also be due to a real relationship between trial size and
effect size, for example, when larger trials have lower compliance,
and compliance is positively related to effect size. In the event that
we find such a relationship, we will examine clinical diversity of
the studies (Section 10.4) (Higgins 2011b). As a direct test for
publication bias, we will compare results extracted from published
journal reports with results obtained fromother sources (including
correspondence).
Data synthesis
RCTs, CCTs, and CBAs
To perform meta-analyses of continuous data, we will input data
on means, standard deviations, and the number of participants for
each outcome in each group. It is important to note that, in all
cases, these means and standard deviations will be unadjusted for
confounders, however, they will be adjusted for clustering when
needed.
Where baseline data are available from RCTs, CCTs and CBAs,
pre-intervention and post-intervention means and scores will be
reported for both the educational intervention(s) and control
groups and the absolute change from baseline will be calculated
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(change in study group values minus change in control group val-
ues), along with standard deviations and 95% CI where possible.
If standard deviations (SD) for change are not given, we will cal-
culate them. In performing our meta-analysis, we will use the in-
verse-variance random-effects model.
ITS
For discrete outcomes (for example, increase in knowledge score
versus no increase in knowledge), we will present the relative risk
of the outcome compared to the control group. We will also cal-
culate the risk difference, that is, the absolute difference in the
proportions in each intervention group. Finally, we will calculate
the number needed to treat for an additional beneficial outcome
such as prevention of one incidence of diabetic foot ulceration or
amputation.
’Summary of findings’ tables
We will construct ’Summary of findings’ (SoF’s) tables for the
primary outcomes and for the first five of the secondary outcomes
listed earlier. Provided there is an adequate number of studies
from developing versus developed countries (i.e. three or more in
each group), we will develop separate tables for developing and
developed country settings and for significant subgroups using the
GRADE protocol (Guyatt 2011).
Data will be synthesised for all studies. If the included studies are
not sufficiently homogeneous to combine in a meta-analysis, we
will use the methods described in the Cochrane Handbook for Sys-
tematic Reviews of Interventions (section 13.6.2.4) (Higgins 2011a)
to present the data . We will display the results of included studies
in a forest plot, but suppress the pooled estimate, while sorting
studies by design feature and according to the developing versus
developed country categories.
Subgroup analysis and investigation of heterogeneity
We will conduct subgroup analyses based on a priori clinical
knowledge, and possible sources of variation among studies sug-
gested byDeeks 2011. Additionally, wewill also perform subgroup
analyses based on the intervention-specific categories listed below:
1. Developed versus developing country as defined by the
World Bank (World 2011).
2. Healthcare setting (e.g. podiatry clinics versus general
hospitals versus general practice).
3. Category of healthcare professional (medical doctor versus
other).
4. Foot-care specific intervention versus composite diabetes
interventions.
Meta-regression
If heterogeneity is an issue, we will conduct meta-regression to
assess the relation of size of effect to characteristics of the trials.
The characteristics we will include in the meta-regression will be
country, healthcare setting, and category of healthcare profession-
als (as above).
Sensitivity analysis
Wewill use sensitivity analyses (1) to assess the robustness of results
by including only studies at overall low risk of bias, and (2) to
assess the robustness of results to variations in the estimated values
of ICC.
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